At a time of extreme financial pressure on the health service, the tension between providing medicines at an affordable cost and the need to fund the development of innovative and increasingly sophisticated medicines is particularly acute. In a series of notes we look at the current state of pharmaceutical pricing regulation in the UK and consider changes on the horizon. Read more